Edition:
United States

Pain Therapeutics Inc (PTIE.O)

PTIE.O on Nasdaq

0.89USD
9:48am EDT
Change (% chg)

$-0.05 (-5.38%)
Prev Close
$0.94
Open
$0.94
Day's High
$0.96
Day's Low
$0.88
Volume
230,397
Avg. Vol
866,099
52-wk High
$3.00
52-wk Low
$0.51

Latest Key Developments (Source: Significant Developments)

Pain Therapeutics announces resignation of Peter Roddy as CFO
Friday, 17 Feb 2017 09:02am EST 

Pain Therapeutics Inc :On Feb 14, 2017, Peter Roddy resigned, effective March 9, 2017, as vice president, chief financial officer.  Full Article

Pain Therapeutics reports qtrly loss per share $0.06
Friday, 17 Feb 2017 09:00am EST 

Pain Therapeutics Inc : Pain therapeutics reports 2016 financial results . Qtrly loss per share $0.06 .Pain Therapeutics - in first two quarters of 2017, company expects its quarterly net cash burn rate will range from $2.0 million to $2.5 million.  Full Article

Pain Therapeutics to discuss remoxy ER with FDA
Tuesday, 20 Dec 2016 09:00am EST 

Pain Therapeutics Inc: Pain therapeutics to discuss remoxy® ER with FDA . Plans to meet with FDA in person on Monday, February 13, 2017 to discuss regulatory path forward for remoxy ER . Pain therapeutics - during its upcoming meeting with FDA, company plans to open a scientific dialogue around intranasal (snorting) route of abuse . Company will provide details of this FDA meeting after receipt of final meeting minute .Pain therapeutics - company believes remoxy ER's thick, sticky, high-viscosity drug mass is a key feature of its abuse deterrent properties.  Full Article

Pain Therapeutics Q2 loss per share $0.07
Tuesday, 19 Jul 2016 04:30pm EDT 

Pain Therapeutics Inc : Pain Therapeutics reports Q2 2016 financial results .Q2 loss per share $0.07.  Full Article

Durect says PDUFA date for remoxy NDA of Sept 25 unchanged
Friday, 1 Jul 2016 09:05am EDT 

Durect Corp : Says prescription drug user fee act (PDUFA) date for remoxy NDA of September 25, 2016 is unchanged . An FDA advisory committee meeting for remoxy is not needed and no change to September 25, 2016 PDUFA date . Pain Therapeutics stated that FDA advised them that regulatory review of remoxy new drug application (NDA) remains active and on-going .Durect provides remoxy update.  Full Article

Pain Therapeutics announces positive top-line results from Human Abuse Potential Study With REMOXY
Tuesday, 12 May 2015 08:01am EDT 

Pain Therapeutics Inc:Announces top-line results of an FDA Category 3 Human Abuse Potential Study with REMOXY Extended-Release Capsules CII, its lead drug candidate that is specifically designed to discourage certain common methods of drug tampering and misuse.This study demonstrated with statistical significance ( p <0.0001) that both intact and chewed REMOXY were less "liked" than immediate-release oxycodone on the two primary endpoints, Drug Liking and Drug High.The Abuse Potential study was conducted in non-dependent, recreational opioid users, as recommended by FDA guidelines.  Full Article

Pain Therapeutics Inc announces material definitive agreement - Form 8-K
Wednesday, 6 May 2015 06:04am EDT 

Pain Therapeutics Inc:Says sent letter to Durect Corp. pursuant to development and license agreement, dated as of Dec. 19, 2002.As amended (DLA), that provided Durect with formal written notice that company is deleting, effective as of Jan. 12, 2015, opioid drug hydrocodone (and only hydrocodone) as a licensed product under the DLA.Letter does not alter terms of DLA regarding remaining three licensed products (REMOXY, hydromorphone or oxymorphone) or otherwise amend the DLA.For avoidance of doubt, all terms and conditions of DLA remain in full force and effect with respect to REMOXY, hydromorphone and oxymorphone.  Full Article

More From Around the Web